Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATP 150

Next Previous
Drug Profile

ATP 150

Alternative Names: ATP-150

Latest Information Update: 28 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amal Therapeutics
  • Developer Amal Therapeutics; Boehringer Ingelheim
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Adenocarcinoma

Most Recent Events

  • 28 Apr 2026 No recent reports of development identified for phase-I development in Adenocarcinoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral, Injection)
  • 28 Apr 2026 No recent reports of development identified for phase-I development in Adenocarcinoma(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (Parenteral, Injection)
  • 10 Jan 2026 ATP 150 is still in phase I trials for Adenocarcinoma in the US (NCT05846516)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top